Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P10914
UPID:
IRF1_HUMAN
Alternative names:
-
Alternative UPACC:
P10914; Q96GG7
Background:
Interferon regulatory factor 1 (IRF1) plays a pivotal role in the regulation of immune responses, cell proliferation, and apoptosis. It acts as both a transcriptional activator and repressor, influencing the expression of genes involved in antiviral, antibacterial, and anti-proliferative responses, as well as apoptosis and immune system processes.
Therapeutic significance:
Given its involvement in gastric cancer and its broad regulatory functions in immune responses and cell cycle regulation, targeting IRF1 presents a promising avenue for therapeutic interventions in cancer treatment and immune modulation.